Abcellera Biologics Inc (ABCL)

$6.93 +0.40 (6.13%)
Market Cap 1.99B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 6,823,400
Avg Vol 6,656,706
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 97%
Beta 1.20
Analysts Strong Sell
Price Target $10.62

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
mikesterz7
mikesterz7 Aug. 8 at 4:19 PM
$ABCL AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
0 · Reply
JonathanRosso871
JonathanRosso871 Aug. 8 at 4:18 PM
$DKNG $ABCL $ACHR $HROW $SG DraftKings continues expanding online betting, AbCellera uses AI in antibody discovery, Archer advances electric aviation, Harrow expands ophthalmology treatments, and SG remains execution-driven. I'm watching customer growth, regulatory milestones, and margins.
0 · Reply
tradersunion353
tradersunion353 Aug. 8 at 3:59 PM
$ABCL over hyped to max lets see how company is going to reward shareholders
1 · Reply
MelvinHurst1057
MelvinHurst1057 Aug. 8 at 3:38 PM
$DKNG $ABCL $ACHR $HROW $SG DraftKings continues expanding online betting, AbCellera uses AI in antibody discovery, Archer advances electric aviation, Harrow expands ophthalmology treatments, and SG remains execution-driven. I'm watching customer growth, regulatory milestones, and margins.
0 · Reply
EquityBlueprint
EquityBlueprint Aug. 8 at 3:29 PM
Prepping for a high-volatility week. Key catalysts & technical setups: $RKLB | Earnings Monday AMC, space focus high $ABCL | Phase 2 readout pending $SNAP | Text-book cup and handle coiling $QCOM | Bullish continuation setup in play $MRVL | Semiconductor momentum looking for continuation Aligning catalysts with structure creates symmetrical edge. I shared this execution framework before, but you weren't following me yet. You're here now.
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 8 at 2:19 PM
$ABCL I’ll just leave this right here… Enjoy ☺️ 10 Days to Cover
2 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 8 at 2:12 PM
$ABCL It could be worth $50B MC to the company if you assume 3-5x 10-20B peak sales. The numbers are insane when you start stacking multiple late stage assets + the T cell engager deals providing several billion in what seems like high margin revenue (note Carl’s comments saying it’s Largely built out and isn’t requiring structural changes in headcount)
0 · Reply
FGA
FGA Aug. 8 at 2:02 PM
$ABCL Have a great weekend and an awesome week!
0 · Reply
Stockingtrade
Stockingtrade Aug. 8 at 1:20 PM
$ABCL How high will the stock go Monday? $12? $15? $20?? Will it stabilize in the teens, or keep gaining??
2 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 8 at 1:18 PM
$ABCL $ABCL AbCellera reporting Phase 2 data early on Monday before the bell feels like a big F U to the shorts…good luck covering 😂
0 · Reply
Latest News on ABCL
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Aug 7, 2026, 4:30 PM EDT - 22 hours ago

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:20:50.000Z - 2 days ago

AbCellera price target raised to $9 from $8 at Stifel

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

2026-08-06T12:12:02.000Z - 2 days ago

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 2 days ago

AbCellera Biologics Earnings Call Transcript: Q2 2026

AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 2 days ago

AbCellera Biologics Slides: Q2 2026

AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 2 days ago

AbCellera Biologics Earnings release: Q2 2026

AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 2 days ago

AbCellera Biologics Quarterly report: Q2 2026

AbCellera Reports Q2 2026 Business Results

Aug 5, 2026, 4:05 PM EDT - 2 days ago

AbCellera Reports Q2 2026 Business Results

AbCellera announces collaboration with Vertex Pharmaceuticals

2026-07-29T11:27:06.000Z - 10 days ago

AbCellera announces collaboration with Vertex Pharmaceuticals

VRTX

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

Jul 29, 2026, 7:00 AM EDT - 10 days ago

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

2026-07-09T21:29:02.000Z - 4 weeks ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

Jul 7, 2026, 4:05 PM EDT - 4 weeks ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 4 weeks ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 4 weeks ago

AbCellera apponts Lynn Seely to board of directors

LYEL

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 4 weeks ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Jun 17, 2026, 7:43 AM EDT - 7 weeks ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jun 17, 2026, 7:00 AM EDT - 7 weeks ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 2 months ago

AbCellera appoints Victor Sandor to board of directors

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:40 AM EDT - 2 months ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 3 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 3 months ago

AbCellera price target raised to $8 from $7 at Stifel

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings release: Q1 2026

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Quarterly report: Q1 2026

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Slides: Q1 2026

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 11, 2026, 4:05 PM EDT - 3 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 7, 2026, 4:05 PM EDT - 3 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 3 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

AbCellera Biologics Slides: Corporate presentation

May 1, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Slides: Corporate presentation

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 21, 2026, 1:30 PM EDT - 3 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 20, 2026, 9:00 AM EDT - 3 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 4 months ago

AbCellera initiated with a Buy at JonesResearch

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 1, 2026, 4:05 PM EDT - 4 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 17, 2026, 4:30 PM EDT - 5 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 5 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Annual report: Q4 2025

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings release: Q4 2025

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Slides: Q4 2025

AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 5 months ago

AbCellera Reports Full Year 2025 Business Results

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Feb 11, 2026, 4:05 PM EST - 6 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 7 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 7 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 7 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 8 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 8 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:00 AM EST - 8 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 9 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Quarterly report: Q3 2025

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings release: Q3 2025

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Slides: Q3 2025

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 11 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 1 year ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 2 years ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 11:30 AM EDT - 2 years ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 2 years ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024

AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024

AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024

AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 2 years ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

mikesterz7
mikesterz7 Aug. 8 at 4:19 PM
$ABCL AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
0 · Reply
JonathanRosso871
JonathanRosso871 Aug. 8 at 4:18 PM
$DKNG $ABCL $ACHR $HROW $SG DraftKings continues expanding online betting, AbCellera uses AI in antibody discovery, Archer advances electric aviation, Harrow expands ophthalmology treatments, and SG remains execution-driven. I'm watching customer growth, regulatory milestones, and margins.
0 · Reply
tradersunion353
tradersunion353 Aug. 8 at 3:59 PM
$ABCL over hyped to max lets see how company is going to reward shareholders
1 · Reply
MelvinHurst1057
MelvinHurst1057 Aug. 8 at 3:38 PM
$DKNG $ABCL $ACHR $HROW $SG DraftKings continues expanding online betting, AbCellera uses AI in antibody discovery, Archer advances electric aviation, Harrow expands ophthalmology treatments, and SG remains execution-driven. I'm watching customer growth, regulatory milestones, and margins.
0 · Reply
EquityBlueprint
EquityBlueprint Aug. 8 at 3:29 PM
Prepping for a high-volatility week. Key catalysts & technical setups: $RKLB | Earnings Monday AMC, space focus high $ABCL | Phase 2 readout pending $SNAP | Text-book cup and handle coiling $QCOM | Bullish continuation setup in play $MRVL | Semiconductor momentum looking for continuation Aligning catalysts with structure creates symmetrical edge. I shared this execution framework before, but you weren't following me yet. You're here now.
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 8 at 2:19 PM
$ABCL I’ll just leave this right here… Enjoy ☺️ 10 Days to Cover
2 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 8 at 2:12 PM
$ABCL It could be worth $50B MC to the company if you assume 3-5x 10-20B peak sales. The numbers are insane when you start stacking multiple late stage assets + the T cell engager deals providing several billion in what seems like high margin revenue (note Carl’s comments saying it’s Largely built out and isn’t requiring structural changes in headcount)
0 · Reply
FGA
FGA Aug. 8 at 2:02 PM
$ABCL Have a great weekend and an awesome week!
0 · Reply
Stockingtrade
Stockingtrade Aug. 8 at 1:20 PM
$ABCL How high will the stock go Monday? $12? $15? $20?? Will it stabilize in the teens, or keep gaining??
2 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 8 at 1:18 PM
$ABCL $ABCL AbCellera reporting Phase 2 data early on Monday before the bell feels like a big F U to the shorts…good luck covering 😂
0 · Reply
MelvinHurst1057
MelvinHurst1057 Aug. 8 at 11:25 AM
$DKNG $ABCL $ACHR $HROW $SG DraftKings continues expanding online betting, AbCellera uses AI in antibody discovery, Archer advances electric aviation, Harrow expands ophthalmology treatments, and SG remains execution-driven. I'm watching customer growth, regulatory milestones, and margins.
0 · Reply
AvidSkier9900
AvidSkier9900 Aug. 8 at 10:39 AM
$ABCL Head of Strategic Finance & Investor Relations shared the Monday news on his personal LinkedIn feed. Probably wouldn’t do that if he knew it was anything less than stellar news…
0 · Reply
Stockingtrade
Stockingtrade Aug. 8 at 3:55 AM
$ABCL Madrigal’s stock went from $64 ($1.4 bn cap) to $234 (5bn) the day after it reported good results from its clinical trial. Crossing my fingers for $ABCL to hit $20 on Monday!
1 · Reply
PeelonDusk
PeelonDusk Aug. 8 at 3:31 AM
$ABCL Back to all time highs 😏
1 · Reply
GinoGino
GinoGino Aug. 8 at 3:07 AM
$ABCL The sequence and timing of the events from the ER, to the Friday PR, and Monday morning data release and call indicate strong results. Based on my experience, two companies, IDEAYA (2026), and Madrigal (2022), had similar set up for their data release and both results were exceptionally strong. I look forward a very beautiful and exceptionally green Monday!
0 · Reply
Stockingtrade
Stockingtrade Aug. 8 at 3:06 AM
$ABCL Would NOT want to be holding a short position on Monday. Going to get ugly for shorts, fast.
0 · Reply
topstockalerts
topstockalerts Aug. 8 at 2:15 AM
$ABCL sometimes the best moves are the least dramatic.
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 8 at 1:44 AM
$ABCL You don’t sit on good data, let’s go $ABCL
0 · Reply
Tradeforincome
Tradeforincome Aug. 8 at 12:50 AM
$ABCL alright guys. Do your part and pump this. Message telegram and discord groups to manipulate this up. We will need new bag holders willing to chase this.
3 · Reply
BiobankerPhD
BiobankerPhD Aug. 8 at 12:16 AM
$ABCL Expect a big sell the news event on Monday
1 · Reply
SPMudson
SPMudson Aug. 8 at 12:05 AM
$ABCL nice set up by management 🤞
0 · Reply
Tradeforincome
Tradeforincome Aug. 7 at 11:24 PM
$ABCL looks like a PR pump to set up an offering next week. the company has described its position as ending the quarter with over $565 million in total cash balances and marketable securities (including the restricted cash), plus ~$110 million in available non-dilutive government funding, for total available liquidity of over $675 million.
4 · Reply